Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Moderna Ships Coronavirus Vaccine for Clinical Trials

publication date: Feb 25, 2020

Moderna has shipped its first batch of mRNA-1273, a coronavirus vaccine, for a US Phase I clinical trial scheduled for April. The company prepared the candidate in 42 days from initial sequencing of the virus, which it called an "indoor record." It described mRNA-1273 as an mRNA vaccine that encodes for a prefusion stabilized form of the Spike (S) protein. Moderna, a Cambridge, MA company developing messenger RNA (mRNA) therapeutics and vaccines, said manufacturing of the initial batch was underwritten by Oslo's Coalition for Epidemic Preparedness Innovations (CEPI). More details....

Stock Symbol: (NSDQ: MRNA)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.